Fertility Tourism Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service (In-Vitro Fertilization, Artificial Insemination, Others), By Application (infertility Treatment, Sex Selection, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Fertility Tourism Market was valued at USD 1.64 billion in 2024 and is expected to reach USD 5.76 billion by 2030 with a CAGR of 23.29% during the forecast period. The global market for Fertility Tourism is experiencing significant growth, driven by growing prevalence of infertility and couples going for different kinds of fertility treatments. The changing lifestyle patterns and prevalence of obesity, different reproductive disorders, among others have significantly increased the infertile population requiring treatment. Studies, suggest that Taiwan, South Korea, Singapore, Macau, and Hong Kong are the top five countries with lowest fertility as of 2021. The lack of effective fertility treatments in these countries makes people travel to other parts of the world to get treatment. For instance, Malaysia is a hotspot in the Asia Pacific region for getting in-vitro fertilization treatments done on account of high success rate. All these countries are in Asia Pacific region and people from these countries go to Malaysia and other parts of the world for getting their in-vitro fertilization treatments done. The world’s average success rate is 50 per cent, but Malaysia’s success rate is about 65 per cent on average. Besides, increasing the insurance coverage for in-vitro fertilization procedures due to male infertilities and ovarian failures will further boost the fertility tourism market in the forecast period.

Key Market Drivers

Declining Fertility Rates and Later Childbearing Increasing Demand for ART Abroad

One of the most powerful forces driving fertility tourism is the global decline in fertility rates combined with the trend of delayed parenthood. In the United States, the Centers for Disease Control and Prevention (CDC) reported 3.6 million births in 2023, with a general fertility rate of 54.5 births per 1,000 women aged 15–44—the lowest in decades. The total fertility rate (TFR) stood at 1.62, far below the replacement level of 2.1. More importantly, births among women aged 30–34 now surpass those among 25–29, highlighting a cultural and economic shift toward later childbearing. In Europe, the situation is even more pronounced. According to Eurostat, the EU TFR dropped to 1.38 in 2023, with 3.67 million births, marking a sharp 5.4% decline compared to 2022. Similarly, Statistics Korea reported a TFR of 0.72 in 2023, while Japan’s Ministry of Health placed its TFR at 1.20. These levels are historically low and signal growing reliance on assisted reproductive technologies (ART) to achieve parenthood.

As fertility windows shrink and age-related risks increase, couples and individuals seek cross-border solutions where advanced technologies, donor gametes, and faster access are available. This demographic reality ensures a sustained and rising demand for fertility tourism worldwide.

Policy Differences and Pro-Access Reforms Creating Global Pull Factors

A second key driver is the variation in national regulations and eligibility rules for ART, which pushes patients to travel abroad when options at home are limited. For example, the UK Human Fertilisation and Embryology Authority (HFEA) sets global benchmarks by publishing transparent clinic outcomes, regulating add-ons, and ensuring patients have access to accurate success-rate data. This transparency makes the UK a magnet for international patients. In Asia, Singapore legalized elective egg freezing (EEF) from July 1, 2023, and extended the eligible age limit from 35 to 37 years, citing evidence that egg quality remains largely stable until then. The Ministry of Health (MOH) Singapore also published clear cost frameworks and medical protocols, reducing uncertainty for both local and international patients.

 Meanwhile, Japan and South Korea, despite facing record-low fertility rates, continue to reform infertility coverage and broaden awareness, indirectly boosting cross-border interest as patients seek clinics offering faster or more flexible treatments abroad. Thus, policy liberalization and differences in access remain strong pull factors for fertility travelers worldwide.

Download Free Sample Report

Key Market Challenges

Legal Complexities and Parentage Recognition Across Borders

One of the biggest hurdles in fertility tourism is navigating legal and parentage rules. Laws governing surrogacy, donor gametes, and ART vary significantly between countries. Even when treatments succeed medically, securing citizenship and legal parenthood for children born abroad can be complex. In the United States, for example, children born overseas through IVF or surrogacy are eligible for citizenship under updated federal rules, but parents must provide genetic evidence, gestational links, and extensive documentation before passports are issued. This process can take months, creating stress for families.

Elsewhere, countries restrict surrogacy to married heterosexual couples or residents only, while others require court orders to finalize parentage. Such legal fragmentation and frequent policy changes add uncertainty, risk, and cost to the fertility tourism process. Families must invest heavily in legal advice, raising overall treatment costs beyond medical expenses alone.

Inconsistent Oversight and Quality Standards Among Countries

The second major challenge is the wide variability in clinical oversight and transparency across destinations. In countries like the UK, the HFEA licenses clinics, enforces data reporting, and evaluate add-on treatments with evidence ratings. This ensures patients can make informed decisions based on reliable data. In contrast, many popular fertility tourism destinations lack comparable regulations or publish little reliable outcome data. Patients may be misled by aggressive marketing that exaggerates success rates or promotes unproven add-ons. Additionally, continuity of care across borders is often poor. Patients may undergo initial testing at home, stimulation and retrieval abroad, and post-treatment care again at home, creating gaps in monitoring and raising the risk of complications such as ovarian hyperstimulation syndrome (OHSS).

Language barriers, non-standard consent practices, and unclear embryo ownership rules further complicate treatment abroad. These inconsistencies make due diligence on clinical quality and regulatory frameworks one of the toughest challenges for patients considering cross-border fertility treatment.

Key Market Trends

Liberalization of Fertility Preservation Policies Worldwide

A significant trend is the global normalization of fertility preservation. Governments are recognizing social and demographic pressures and updating laws accordingly. In Singapore, the introduction of elective egg freezing (EEF) in 2023 and the extension of the age limit to 37 years marked a watershed moment. The MOH’s detailed cost guidelines and clinical standards allow women to preserve fertility with confidence and transparency. This move not only addresses local needs but also positions Singapore as a fertility tourism hub in Asia, attracting regional patients seeking clarity and legal safety.

Similarly, the UK continues to lead in transparent ART regulation. The HFEA publishes age-specific live birth rates and reviews the evidence base for emerging lab technologies. Patients worldwide use these metrics as a benchmark when choosing clinics abroad. This trend of policy liberalization and information transparency is expected to spread, as governments respond to declining fertility rates by offering citizens more options—indirectly fueling cross-border demand for countries with the clearest rules and modern preservation laws.

Older Patient Demographics Driving Demand for Advanced ART Techniques

Another emerging trend is the shift in patient demographics toward older age groups. According to the CDC, U.S. births among women aged 30–34 now outnumber those aged 25–29, reflecting the global trend of delayed childbearing. As ovarian reserve declines with age, demand for advanced laboratory techniques has grown.

Technologies like preimplantation genetic testing (PGT), improved embryo culture systems, and single-embryo transfer protocols are increasingly used to optimize outcomes for patients in their late 30s and 40s. Regulators like the HFEA provide evidence ratings for add-ons, ensuring patients understand which techniques are clinically beneficial and which remain experimental. In parallel, fertility preservation strategies such as early egg freezing are gaining popularity. Many women freeze eggs in their home country or abroad and later pursue IVF cycles when ready to conceive. The combination of older patients seeking ART and younger patients opting for preservation is reshaping the patient mix in fertility tourism markets, with a stronger emphasis on advanced technologies, data-driven decision-making, and cumulative live-birth rates per retrieval.

Segmental Insights

Service Insights

Based on Service, In-Vitro Fertilization (IVF) accounts for the largest market share under the service category. IVF remains the cornerstone of assisted reproductive technologies (ART) because it addresses a wide spectrum of infertility issues, including advanced maternal age, blocked fallopian tubes, endometriosis, male factor infertility, and unexplained infertility. Its versatility and higher success rates compared to other procedures make it the most sought-after treatment among fertility tourists. The scale of demand is reflected in government statistics. According to the Centers for Disease Control and Prevention (CDC), more than 91,000 live births in the United States in 2021 (latest full-year figures) were a result of ART procedures, with IVF accounting for the overwhelming majority. Similarly, in Europe, data collected by Eurostat and national health registries show IVF to be the dominant treatment type across ART cycles, with countries such as Spain, Greece, and the Czech Republic hosting large numbers of international patients for IVF-based services.

Download Free Sample Report

Regional Insights

Based on the region, North America dominates the global fertility tourism market, holding the largest market share. This leadership is driven by several factors, including advanced healthcare infrastructure, the presence of world-class fertility clinics, and high awareness and acceptance of assisted reproductive technologies (ART). The United States plays a central role as it combines cutting-edge clinical practices with transparent regulatory oversight. The Centers for Disease Control and Prevention (CDC) actively collects and publishes ART success rate data through its annual ART Surveillance Report, which makes the U.S. one of the most transparent markets globally for fertility outcomes. The region also benefits from rising infertility rates and delayed parenthood trends. According to the CDC, the total fertility rate (TFR) in the U.S. was 1.62 in 2023, well below the replacement rate of 2.1, underscoring the growing reliance on ART. In addition, the average age of first-time mothers has risen to 30 years, intensifying demand for advanced fertility treatments. Many international patients are attracted to North America for procedures such as preimplantation genetic testing (PGT), egg freezing, and donor gametes, which are offered under strict medical protocols and well-defined legal frameworks.

Recent Developments

• In June 2024, Sabine Hospitals successfully raised USD 50 million in a recent funding round. This financial boost was primarily led by CX Partners, a prominent investment firm known for its focus on healthcare and technology sectors. The infusion of capital is expected to enhance the hospital’s capabilities, expand its services, and improve patient care.
• In March 2024, TMRW Life Sciences (TMRW), a company focused on advancing fertility technology and improving IVF laboratory standards, launched CryoLink. This workstation is designed to enhance the digital management of frozen specimen inventories in fertility clinics. With the introduction of CryoLink, users can operate TMRW’s Digital Specimen Management system either independently or alongside TMRW’s automated storage solutions.
• In September 2023, Sion Hospital, Mumbai, started offering free infertility treatment, including various diagnostic procedures, ART, and counseling services designed to support couples throughout their journey. The primary objective of this program is to make treatments more accessible, especially for those who may not have the financial means to afford such services. The initiative also seeks to raise awareness about reproductive health issues in the community.
• In September 2023, Merck introduced a comprehensive Fertility Benefit program in to provide financial assistance for treatments to employees across eight markets: Germany, the UK, Switzerland, China, India, Taiwan, Brazil, and Mexico. Currently, Merck offers similar benefits to its workforce in the U.S., Canada, and Japan.
• In August 2023, the CK Birla Group’s Birla Fertility & IVF announced its plans to invest USD 59.4 million over the next 2-3 years to increase its market share within the domestic sector. Birla Fertility & IVF aims to expand its footprint in southern India by opening 10-12 new centers across Karnataka, Tamil Nadu, Kerala, Telangana, and Andhra Pradesh within the next 12-24 months.

Key Market Players

• Manchester Fertility Services Ltd
• San Diego Fertility Center
• Eva Fertility Clinics
• The Surrey Park Clinic
• Bumrungrad International Hospital
• Assisted Reproduction and Gynecology Centre
• Sincere IVF Center
• Alpha IVF & Women’s Specialists
• Genesis IVF
• Apollo Fertility

Report Scope:

In this report, the Global Fertility Tourism Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Fertility Tourism Market, By Service:

o   In-Vitro Fertilization

o   Artificial Insemination

o   Others

• Fertility Tourism Market, By Application:

o   Infertility Treatment

o   Sex Selection

o   Others

• Fertility Tourism Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Fertility Tourism Market.

Available Customizations:

Global Fertility Tourism Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Fertility Tourism Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]